What is ALZN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ALZN?

P/E (TTM) is n/a and 52-week range is $0.84 to $2.68 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ALZN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ALZN?

The company profile lists net income (TTM) near $-11M, EPS (TTM) near $-2.27 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Alzamend Neuro Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Atlanta, Georgia, US, 4.8M shares outstanding, ISIN US02262M6057 when available from company profile and filing metadata.

Alzamend Neuro Inc

$ALZN

Health Care · Biotechnology

IR Run Scenarios

$1.34

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company is headquartered in Atlanta, Georgia and currently employs 4 full-time employees. The company went IPO on 2021-06-15. The firm is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The firm's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees

Website

alzamend.com/

IPO

2021-06-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)